F. Belal

A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms

A simple, rapid and sensitive HPLC method has been developed for the simultaneous determination of ramipril and hydrochlorothiazide in their dosage forms. Acetonitrile: sodium perchlorate solution (0.1 M) adjusted to pH 2.5+/-0.2 with phosphoric acid (46:54 v/v), was used as the mobile phase, at a flow rate of 1.5 ml/min. A supelcosil LC-8 column (5 microm), 15 cm x 4.6 mm i.d. was utilized as stationary phase. Detection was affected spectrophotometrically at 210 nm. Clobazam was used as an internal standard. The method was also applied for the determination of ramipril in the presence of its degradation products. Linearity ranges for ramipril and hydrochlorothiazide were 4.5-45 and 0.6-14 microg/ml, respectively. Minimum detection limits (S/N = 2) obtained were 180 and 23 ng/ml for ramipril and hydrochlorothiazide, respectively. The proposed method was further applied to the analysis of tablets containing the two drugs, the percentage recoveries +/- S.D. (n = 5) were 100.45%+/-0.63 and 99.55%+/-0.78 for ramipril and hydrochlorothiazide, respectively.

Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine

A stability-indicating, sensitive, simple and selective spectrofluorimetric method was developed for the determination of vigabatrin (VG) and gabapentin (GB). The method is based on the reaction between the two drugs and fluorescamine in borate buffer of pH 8.2 to give highly fluorescent derivatives that are measured at 472 nm using an excitation wavelength of 390 nm for both drugs. The optimum conditions were ascertained and the method was applied for the determination of VG and GB over the concentration range of 0.20-4.00 and 0.1-1.0 microg/ml, respectively with detection limits of 0.05 microg/ml (2.9 x 10(-7) M) and 0.06 microg/ml (2.3 x 10(-7) M) for VG and GB, respectively. The suggested method was applied, without any interference from the excipients, to the determination of the two drugs in their pharmaceutical formulations. Furthermore, the method was extended to the in-vitro determination of both drugs in spiked human urine. Interference from endogenous amino acids could be eliminated through selective complexation with copper acetate, the % recovery (n=4) is 98.0 +/- 7.05. Co-administered drugs such as lamotrigine, phenobarbitone, valproic acid, clopazam, carbamazepine, clonazepam and cimitidine did not interfere with the assay. The method is also stability-indicating; as the degradation product of vigabatrin: 5-vinylpyrrolidin-2-one, produced no interference with its analysis.

Kinetic spectrophotometric determination of nizatidine and ranitidine in pharmaceutical preparations.

A new simple and sensitive kinetic spectrophotometric method is described for analysis of nizatidine (I) and ranitidine (II). The method involves the reaction of the drugs with alkaline potassium permanganate, whereby a green color peaking at 610 nm is produced. The reaction is monitored spectrophotometrically by measuring the rate of change of absorbance of the resulting manganate species at 610 nm. Calibration graphs are linear over the concentration range 0.8-4.0 microg/ml and the precision (% RSD 1.80, 1.53 for I and II, respectively) is quite acceptable. The method is satisfactorily applied for direct analysis of pharmaceutical preparations containing I and II. A proposal of the reaction pathway is postulated.

Simple spectrophotometric determination of cinnarizine in its dosage forms.

A direct, extraction-free spectrophotometric method has been developed for the determination of cinnarizine in pharmaceutical preparations. The method is based on ion-pair formation between the drug and three acidic (sulphonphthalein) dyes; namely bromocresol green (BCG), bromocresol purple (BCP) and bromophenol blue (BPB) which induces an instantaneous bathochromic shift of the maximum in the drug spectrum. Conformity to Beers law enabled the assay of dosage forms of the drug. Compared with a reference method, the results obtained were of equal accuracy and precision. A more detailed investigation of the cinnarizine-BCG ion pair complex was made with respect to its composition, association constant and free energy change. In addition, this method was also found to be specific for the analysis of cinnarizine in the presence of some of the co-formulated drugs, such as pyridoxine hydrochloride and digoxin.

Voltammetric determination of isoxsuprine and fenoterol in dosage forms and biological fluids through nitrosation

A simple and highly sensitive voltammetric method was developed for the determination of isoxsuprine HCl (I) and fenoterol HBr (II) in dosage forms and biological fluids. The method is based on treatment of the two compounds with nitrous acid followed by measuring the cathodic current produced by the resulting nitroso derivatives. The voltammetric behavior was studied adopting Direct Current (DCt), Differential Pulse (DPP) and Alternating Current (ACt) polarography. Both compounds produced well-defined, diffusion-controlled cathodic waves over the whole pH range in Britton-Robinson buffers (BRb). At pH 11 and pH 9, the values of diffusion-current constants (Id), were 9.4 +/- 0.3 and 7.7 +/- 0.4 for I and II, respectively. The current-concentration plots for I were rectilinear over the range of 0.6-12 microg/ml and 0.1-12 microg/ml in the DCt and DPP modes, respectively. As for II, the range was 1-20 microg/ml and 0.1-20 microg/ml in the DCt and DPP modes, respectively. The minimum detectability (S/N = 2) were 0.02 microg/ml (approximately 6 x 10(-8) M) and 0.01 microg/ml (approximately 2.6 x 10(-8) M) for I and II, respectively, adopting the DPP mode. The proposed method was applied to the determination of both compounds in dosage forms and the results obtained were in good agreement with those obtained using reference methods. The proposed method was further applied to the determination of isoxsuprine in spiked human urine and plasma. The percentage recoveries adopting the DPP mode were 98.84 +/- 1.18 and 99.26 +/- 0.97, respectively.

Voltammetric analysis of trazodone HCl in pharmaceuticals and biological fluids.

The voltammetric behavior of trazodone (TRZ) HCl was studied using direct current (DC(t)), differential pulse (DPP) and alternating current (AC(t)) polarography. The drug manifests cathodic waves over the pH range of 10-14. The waves were characterized as being irreversible, diffusion-controlled with limited adsorption properties. At pH 10, the diffusion current-concentration relationship was found to be rectilinear over the range 4-32 and 0.8-24 microg ml(-1) using DC(t) and DPP modes, respectively, with minimum detectability (S/N=2) of 0.104 microg ml(-1) (2.45 x 10(-6) M) and 0.314 microg ml(-1) (7.397 x 10(-6) M) using the DPP and DC(t) modes, respectively. The diffusion-current constant (I(d)) is 4.31+/-0.02 (n=6). The proposed method was successfully applied to the determination of the studied compound either in pure form or in formulations. The results obtained were favorably compared with those given using a reference method. Furthermore, the proposed method was applied to the determination of TRZ in spiked human urine and plasma adopting the DPP technique. No prior extraction step is needed in case of urine. The percentage recoveries were 98.43+/-0.79 and 97.44+/-0.705 (n=4) in spiked human urine and plasma, respectively. A pathway for the electrode reaction was postulated.

Spectrofluorometric determination of labetolol in pharmaceutical preparations and spiked human urine through the formation of coumarin derivative.

A simple, sensitive and specific spectrofluorimetric method has been developed for the determination of labetalol (LBT). The method is based on the reaction between LBT and ethylacetoacetate in the presence of sulphuric acid to give yellow fluorescent product with excitation wavelength of 312 nm and emission wavelength of 432 nm. The reaction conditions were studied and optimized. The fluorescence intensity-concentration plot is rectilinear over the range 1-15 microgram/ml with minimum detectability limit of 0.8 microgram/ml (2.16 x 10(-6) M). The proposed method was successfully applied to commercial tablets containing LBT, the percentage recoveries agreed well with those obtained using the official methods. Hydrochlorothiazide, which is frequently co-formulated with LBT did not interfere with the assay. The method was further extended to the in-vitro determination of LBT in spiked human urine samples. The percentage recovery was 101.50+/-6.18 (n=6). A proposal of the reaction pathway was postulated.

Spectrophotometric determination of labetalol in pharmaceutical preparations and spiked human urine

Two simple and sensitive spectrophotometric methods were developed for the spectrophotometric determination of labetaolol (LBT). Both methods are based on the phenolic nature of the drug. The first method (Method I) is based on coupling LBT with diazotized benzocaine in presence of trimethylamine. A yellow colour peaking at 410 nm was produced and its absorbance is linear with the concentration over the range 1-10 microg ml(-1) with correlation coefficient (n=5) of 0.9993. The molar absorptivity was 2.633 x 10(4) l mol(-1) cm(-1). The second method (Method II) involves coupling LBT with diazotized p-nitroaniline in presence of sodium carbonate. An orange colour peaking at 456 nm was obtained and its absorbance is linear with concentration over the range 1-10 microg ml(-1) with correlation coefficient (n=5) of 0.99935. The stoichiometry of the reaction in both cases was accomplished adopting the limiting logarithmic method and was found to be 1:1. The developed method could be successfully applied to commercial tablets. The results obtained were in good agreement with those obtained using the official methods. No interference was encountered from co-formulated drugs, such as hydrochlorothiazide. The method was further extended to the in-vitro determination of LBT in spiked human urine. The % recovery (n=4) were 97.7+/-5.75 and 103.27+/-5.42 using the Methods I and II, respectively.

Fluorimetric determination of oxamniquine in biological fluids

A highly sensitive and specific fluorimetric method was developed for the determination of oxamniquine in biological fluids (urine and plasma). The proposed method is based on the reduction of oxamniquine using zinc/calcium chloride to obtain its nitroso derivative. The latter is then allowed to react with 2-cyanoacetamide to get a highly fluorescent product. The different experimental parameters affecting the intensity of the fluorescence were carefully studied and incorporated into the procedure. Under the described conditions, the method is applicable over the concentration range of 0.08-0.88 microgram/ml with a minimum detectability (S/N = 2) of 8 ng/ml. The percentage recoveries from spiked urine and plasma were 99.75 +/- 1.58 and 97.46 +/- 0.44%, respectively.

A simple kinetic spectrophotometric method for the determination of isoxsuprine in dosage forms.

A simple and sensitive kinetic method was developed for the determination of isoxsuprine in pharmaceutical preparations. The method is based upon a kinetic investigation of the oxidation reaction of the drug with alkaline potassium permanganate at room temperature for a fixed time of 30 min. The absorbance of the coloured manganate ion was measured at 610 nm. Alternatively, the decrease in the absorbance of potassium permanganate after addition of the drug was measured at 525 nm. The absorbance-concentration plots in both procedures were rectilinear over the range of 0.5-4 microg ml(-1) (r = 0.9998) with a minimum detectability of 0.05 microg ml (-1) (1.48 x 10(-7) M). The different experimental parameters affecting the development and stability of the colours were carefully studied and optimized. The determination of isoxsuprine by the fixed concentration and rate constant methods is also feasible with the calibration equations obtained but the fixed time method has been found to be more applicable. Both procedures were applied to the determination of isoxsuprine in formulations. The results obtained were in good agreement with those obtained using a reference method. The proposed method was also adopted to detect isoxsuprine in spiked human plasma at its therapeutic level of concentration (0.4 microg ml(-1)). A proposal of the reaction pathway was postulated.